Seres Therapeutics Valuation
| MCRB Stock | USD 0.71 0.02 2.74% |
Seres Therapeutics is overvalued. Seres Therapeutics has a current Real Value of $0.64 per share. The regular price of the company is $0.71. Our model measures the value of Seres Therapeutics from inspecting the company fundamentals such as Shares Outstanding of 174.36 M, return on equity of -15.56, and Shares Owned By Institutions of 36.18 % as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Seres Therapeutics' valuation include:
Price Book 9.2593 | Enterprise Value | Enterprise Value Ebitda (2.07) | Price Sales 390.2706 | Forward PE 1.6636 |
Overvalued
Today
Please note that Seres Therapeutics' price fluctuation is abnormally volatile at this time. Calculation of the real value of Seres Therapeutics is based on 3 months time horizon. Increasing Seres Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Seres Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Seres Stock. However, Seres Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.71 | Real 0.64 | Target 3.87 | Hype 0.73 | Naive 0.78 |
The real value of Seres Stock, also known as its intrinsic value, is the underlying worth of Seres Therapeutics Company, which is reflected in its stock price. It is based on Seres Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Seres Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Seres Therapeutics helps investors to forecast how Seres stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Seres Therapeutics more accurately as focusing exclusively on Seres Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Seres Therapeutics' intrinsic value based on its ongoing forecasts of Seres Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Seres Therapeutics' closest peers. If more than one evaluation category is relevant for Seres Therapeutics we suggest using both methods to arrive at a better estimate.
Seres Therapeutics Cash |
|
Seres Valuation Trend
Comparing Seres Therapeutics' enterprise value against its market capitalization is a good way to estimate the value of Seres Therapeutics uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Seres Therapeutics Total Value Analysis
Seres Therapeutics is now projected to have valuation of 188.48 M with market capitalization of 127.63 M, debt of 91.64 M, and cash on hands of 195.8 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Seres Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
188.48 M | 127.63 M | 91.64 M | 195.8 M |
Seres Therapeutics Asset Utilization
One of the ways to look at asset utilization of Seres is to check how much profit was generated for every dollar of assets it reports. Seres Therapeutics has a negative utilization of assets of -0.3 %, losing $0.003043 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Seres Therapeutics shows how discouraging it operates for each dollar spent on its assets.Seres Therapeutics Ownership Allocation
Seres Therapeutics shows a total of 174.36 Million outstanding shares. 30% of Seres Therapeutics outstanding shares are owned by institutional holders. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Seres Therapeutics Profitability Analysis
Net Income was 136 K with loss before overhead, payroll, taxes, and interest of (14.53 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Seres Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Seres Therapeutics and how it compares across the competition.
About Seres Therapeutics Valuation
The stock valuation mechanism determines Seres Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Seres Therapeutics. We calculate exposure to Seres Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Seres Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -3.5 M | -3.4 M | |
| Pretax Profit Margin | (1.04) | (1.09) | |
| Operating Profit Margin | (0.98) | (1.03) | |
| Net Loss | (1.04) | (1.09) | |
| Gross Profit Margin | 0.89 | 0.94 |
Seres Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 155.4 M | |
| Forward Price Earnings | 1.6636 |
Seres Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Seres Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Seres we look at many different elements of the entity such as Seres's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Seres Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Seres Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Seres Therapeutics' worth.Complementary Tools for Seres Stock analysis
When running Seres Therapeutics' price analysis, check to measure Seres Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Seres Therapeutics is operating at the current time. Most of Seres Therapeutics' value examination focuses on studying past and present price action to predict the probability of Seres Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Seres Therapeutics' price. Additionally, you may evaluate how the addition of Seres Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Global Correlations Find global opportunities by holding instruments from different markets |